Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 18/20 | 0.54 |
| ▸ | TPO | P07202 | 16/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461789 | 0.80 | MPO (0.48) | MPOTPOKCNH2CYP3A4PNP | |
| SCHEMBL30749245 | 0.77 | MPO (0.54) | MPOTPOKCNH2CYP3A4 | |
| SCHEMBL27223595 | 0.76 | MPO (0.51) | MPOTPOKCNH2CYP3A4 | |
| SCHEMBL30749376 | 0.76 | MPO (0.51) | MPOTPOKCNH2CYP3A4 | |
| SCHEMBL2282123 | 0.74 | MPO (0.63) | MPOTPOKCNH2CYP3A4PNP | |
| SCHEMBL17109096 | 0.72 | HTR6 (0.55) | KCNH2HTR6 | |
| SCHEMBL2454888 | 0.71 | MPO (0.47) | MPOTPOKCNH2CYP3A4 | |
| SCHEMBL16726993 | 0.71 | HTR6 (0.52) | HTR6 | |
| SCHEMBL2457706 | 0.69 | HTR6 (0.41) | HTR6 | |
| SCHEMBL29353520 | 0.68 | HTR6 (0.51) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010535-B1 | THIOXANTHINE DERIVATIVES AND THEIR USE AS INHIBITORS OF MPO | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| US-8026244-B2 | Thioxanthine derivatives and their use as inhibitors of MPO | ASTRAZENECA AB (SE) | 2011-09-27 | — | — | US | disclosed |
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149475-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | MPO 1/4885TPO 12/4885KCNH2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.